Overexpression of cytokines in inflamed joints plays an important role in joint inflammation and in damage to articular tissue. Biological agents aimed at specifically antagonising tumour necrosis factor (TNF) are effective in the treatment of adult rheumatoid arthritis. A recent trial of etanercept, a genetically engineered fusion protein consisting of the Fc domain of human IgG1 and the TNF receptor p75, has demonstrated that this agent is also well tolerated and effective in patients with juvenile idiopathic arthritis (JIA). Etanercept offers a promising new alternative for patients with JIA who have persistently active arthritis despite treatment with methotrexate. Further studies are needed to clarify whether etanercept is equally effective in the various onset types of JIA (oligoarthritis, polyarthritis and systemic arthritis), whether it can modify disease progression and whether it can be administered safely for long periods of time to children.
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood, with an estimated annual incidence of about 1.4 per 10 000 children under the age of 16 years in the US and a prevalence of roughly 1 per 1000. [1, 2] It is a heterogeneous inflammatory disorder that is classified in different subtypes based on the clinical characteristics in the first 6 months of disease. [3] Three principal types of onset are recognised (oligoarthritis, polyarthritis and systemic arthritis). Although the course of JIA is highly variable and largely unpredictable, long term follow-up studies of JIA populations have shown that the disease is not benign and that radiographic joint damage is common and occurs early. [4] Thus, the proportion of children with an unfavourable outcome is now estimated to be greater than once believed.
The traditional approach to treatment of JIA includes use of one of the nonsteroidal anti-inflammatory drugs (NSAIDs) as first-line therapy. Depending on the type of disease onset and the course of arthritis, a significant proportion of all patients do not achieve adequate control with NSAIDs alone. These patients are candidates for more aggressive therapy with second-line agents.
In the past 10 years, methotrexate has become the therapeutic agent of choice for children with JIA who fail to respond adequately to NSAIDs. A number of studies have shown that methotrexate is an effective and well tolerated medication for the treatment of patients with JIA, with 60 to 70% of patients experiencing a significant clinical benefit with the standard dose regimen of 10 to 15 mg/m 2 / week. [5] Furthermore, preliminary evidence has been provided that methotrexate may significantly alter the natural history of JIA. [6, 7] However, a consistent proportion of patients (30 to 40%) do not achieve a satisfactory response to the standard dosage of the drug. Several approaches have been suggested for these patients, including the use of higher doses of methotrexate, up to 25 to 30 mg/m 2 /week, given parenterally [8, 9] or the combination of methotrexate with other second-line agents (sulfasalazine, hydroxychloroquine, azathioprine, or cyclosporin). [10] In the most severe and refractory cases, more aggressive protocols, including combination of weekly methotrexate with monthly pulse intravenous methylprednisolone and cyclophosphamide [11, 12] or autologous haematopoietic stem cell transplantation, [13] have been attempted.
In the last 2 decades, progress in understanding the biology of inflammation has pointed to the pathogenic role of dysregulated production of cytokines in several diseases, including chronic arthritis. Recent biotechnology advances have also allowed the development of new tools that can be used in humans to specifically antagonise the biological activities of a given cytokine for a therapeutic purpose. In this paper we focus first on the rationale for the use of tumour necrosis factor (TNF) inhibitors, particularly etanercept, in the treatment of JIA, taking into consideration the available evidence on cytokine involvement in this disease, and then provide a summary of the results of the only available clinical trial in JIA.
Cytokines in Juvenile Idiopathic Arthritis (JIA)
A wide variety of cytokines are constitutively expressed in inflamed joints (table I). Among the inflammatory cytokines, interleukin (IL)-1, TNF and IL-6 play a major role in induction of the systemic effects of inflammation (table II) . It is clear that in inflamed joints there are cytokines with superimposable, synergistic or antagonistic effects. Moreover, some cytokines induce, or inhibit, the production of other cytokines which are in turn responsible for indirect effects. In the apparent chaos of the multiple interactions between different mediators, some degree of hierarchy exists. In vitro studies on synovial tissues from a patient with adult rheumatoid arthritis demonstrated that neutralisation of TNFα markedly decreased the production of other inflammatory cytokines such as IL-1, IL-6, granulocyte-macrophage colony-stimulating factor and IL-8. This finding, together with the known biological activities of TNF and the effect of TNF inhibition in some animal models of arthritis, provided the rationale for the use of TNF inhibitors in the treatment of adult rheumatoid arthritis. The demonstrated efficacy of etanercept, as well as of the other TNF inhibitors, in the treatment of patients with rheumatoid arthritis provides additional proof of the important role of TNF in this disease.
Compared with adult rheumatoid arthritis, JIA is highly heterogeneous, with respect not only to clinical features but also to genetic background and immunological abnormalities. [14] Moreover, dif- Table I . Effects on articular and periarticular tissues of the cytokines that are most relevant in the pathogenesis of chronic articular inflammation and of damage to articular and periarticular tissues Cytokines Effect The available data concerning cytokines in JIA show that there are indeed differences in the levels of expression of some cytokines between the various JIA onset types and adult rheumatoid arthritis. [15] In addition, recent data in animal models suggest that the pathogenic relevance of a given inflammatory cytokine may be different in different arthritides.
Alonzi et al. [16] observed a striking difference in the role of IL-6 in 2 different animal models of arthritis, collagen-induced arthritis (CIA) in DBAI/J mice and the spontaneous arthritis of TNFα transgenic mice, by back-crossing these 2 strains with IL-6−deficient mice (IL-6-/-). While TNFα transgenic/IL-6-/-mice developed arthritis with an incidence and severity comparable to that of TNFα transgenic mice in which the IL-6 gene was functional, none of the DBAI/J/IL-6-/-mice developed arthritis, demonstrating that IL-6 production is necessary for the development of CIA, but not of the spontaneous arthritis of TNFα transgenic mice.
Moreover, treatment with a monoclonal antibody (MAb) to TNFα clearly suppressed joint swelling in streptococcal cell wall−induced arthritis, but did not markedly affect the course of the arthritis in established CIA. [17] These data show that the same cytokine plays a very different role in different arthritides, with a different hierarchy in the cytokine network in different diseases.
Synovial tissue expression or synovial fluid levels of TNFα, as well as of TNF receptors p55 and p75, have been reported to be similar in the various JIA onset types and comparable to those found in adult rheumatoid arthritis. [18] [19] [20] These observations show that TNFα is activated in the inflamed joints of patients with JIA in a manner similar to that observed in adult rheumatoid arthritis.
Regarding differences in the role played by TNFα in JIA, it is worth mentioning a possible distinctive role of TNF in systemic-onset JIA suggested by the finding of markedly elevated circulating levels of soluble TNF receptors p55 and p75. TNF receptor shedding in a soluble form is believed to be secondary to TNF production, and the measurement of soluble TNF receptors provides an alternative, albeit indirect, way of evaluating the activation of the TNF system in vivo.
In systemic-onset JIA, the markedly elevated levels of soluble TNF receptors were found to be significantly correlated with the systemic symptoms (i.e. fever) and with coagulation abnormalities, including the development of systemic-onset JIA-associated macrophage activation syndrome (MAS). [21] These results are consistent with the well known effect of TNFα on coagulation and the fibrinolytic system, and suggest that, in systemiconset JIA, TNFα may be involved in the pathogenesis of systemic features and the subclinical activation of coagulation and that TNFα overproduction may be responsible for the systemic-onset JIAassociated MAS. Indeed, many features of MAS are characteristically secondary to TNFα hyperproduction in vivo. a For IL-1 and TNF, the inhibition of erythropoiesis is secondary to inhibition of the production of erythropoietin and of the proliferation of red blood cell precursors; for IL-6 it appears to be secondary to an alteration in the metabolism of iron, which is captured and thus not available for erythropoiesis.
+ indicates the relative potency of each cytokine in the indicated effect; -indicates a lack of effect.
It is also worth considering that a vast body of evidence points to increased production of IL-6 as playing a major pathogenic role in the clinical and laboratory manifestations of systemic-onset JIA. Indeed, in this disease, synovial fluid and circulating levels of IL-6 are markedly elevated and significantly higher than those found in the other JIA onset forms or in adult rheumatoid arthritis. [19, 22, 23] Serum IL-6 levels are correlated with a number of features, including the febrile peak, the extent and severity of joint involvement, platelet counts and C-reactive protein levels. The known biological activities of IL-6 (see tables I and II) indicate that prominent production of this cytokine could explain several clinical and laboratory manifestations of systemic-onset JIA, including characteristic complications, such as microcytic anaemia and growth impairment. [24, 25] This led to the hypothesis that systemic-onset JIA is an IL-6-mediated disease. [26] 
Etanercept in JIA
Etanercept is a genetically engineered fusion protein consisting of the extracellular ligand-binding portion of the human TNF receptor (TNFR-p75) fused with the Fc domain of human IgG1. It binds to both TNFα and TNFβ, thereby blocking their interaction with cell surface TNF receptors. Etanercept has been assessed in clinical trials of adults with rheumatoid arthritis [27, 28] and children with JIA. [29] On the basis of the results of these trials, this agent became the first biological response modifier approved by the US Food and Drug Administration for use in both adult rheumatoid arthritis and JIA.
The efficacy and tolerability of etanercept in patients with JIA were evaluated by the Pediatric Rheumatology Collaborative Study Group in an initial 2-part study (part 1, nonblinded; part 2, blinded) and in a subsequent nonblinded extension trial. [29] In part 1 of the study, 69 patients (mean age 10.5 years; range 4 to 17) with polyarticular course JIA and active disease who were refractory or intolerant to methotrexate (≥10 mg/m 2 /week) received etanercept 0.4 mg/kg subcutaneously twice weekly for 90 days. 51 patients (74%) met the JIA definition of improvement [30] at day 90 compared with baseline, defined as a ≥30% improvement in at least 3 of the 6 JIAcore set variables with no more than 1 of the remaining variables worsening by ≥30%.
The 51 responders were subsequently randomised (part 2) to blinded treatment with placebo (n = 26) or etanercept 0.4 mg/kg subcutaneously (n = 25) for 4 months or until disease flare (defined as worsening from day 90 by ≥30% in ≥3 of the 6 variables, improvement by ≥30% in ≤1 variable, and ≥2 active joints). Disease flared within a median of 28 days in 81% of the patients who were randomised to receive placebo, whereas those who remained on etanercept continued their response at 7 months (the end of the study).
Patients were enrolled in a subsequent openlabel extension trial if they had completed the initial study or if they had withdrawn prematurely because of inadequate response or disease flare. 59 patients have received etanercept for up to 12 months in the extension trial and up to 16 months in both studies combined. The therapeutic response achieved by patients who received etanercept in part 2 of the initial study was maintained with continued etanercept treatment in the extension trial. Patients who received placebo in part 2 of the initial study had a significant loss of effect, but this effect was regained when etanercept treatment was restarted in the extension trial. It is noteworthy that all patients discontinued methotrexate treatment 2 weeks before entering the trial; therefore, the observed clinical benefit appears to be entirely due to etanercept.
Etanercept was generally well tolerated in children with JIA. The most frequently reported adverse events were injection site reactions and upper respiratory tract infections that were of mild to moderate intensity and did not result in interruption of etanercept therapy. More children reported abdominal pain (17%) and vomiting (14.5%) than in studies in adult patients (approximately 5%). While receiving etanercept, 2 children developed varicella infections associated with signs and symptoms of aseptic meningitis, but in both the infection resolved without sequelae.
Future Directions
Etanercept has already become an important new therapy for the treatment of rheumatoid arthritis. The experience obtained to date in clinical trials indicates clearly that etanercept is also effective in controlling symptoms in patients with JIA.
Questions remain, however, about the ability of etanercept to slow disease progression in JIA. Based on the preclinical data of the effects of etanercept on TNF, the drug would be expected to slow bone and cartilage destruction. Of note, in a blinded prospective trial in adults with early rheumatoid arthritis comparing etanercept and methotrexate, etanercept was shown to be superior to methotrexate in retarding x-ray-assessed disease progression. [31] Other important questions remaining to be answered include the most advantageous time to start etanercept therapy and whether it should be administered alone or in combination with methotrexate. A controlled trial in adults with rheumatoid arthritis has shown that the combination of etanercept and methotrexate is well tolerated and provides greater clinical benefit than methotrexate alone. [28] Because, as previously mentioned, the different JIA onset types represent different diseases with possibly different etiopathogenetic mechanisms, it will be necessary to evaluate whether treatment with etanercept is equally effective in all onset types. It is worth noting that treatment of 1 patient with severe systemic-onset JIA with infliximab (cA2; a chimaeric MAb directed against human TNFα) resulted in an evident effect on systemic manifestations (i.e. fever), but failed to modify the severity of the arthritis. [32] This observation may be explained by hypothesising that TNFα is not as relevant in the joint inflammation of systemic-onset JIA as it is in adult rheumatoid arthritis, but rather plays an important role in systemic manifestations (see table II).
A possible alternative explanation is provided by the observation that, unlike in adult rheumatoid arthritis, TNFβ expression was detected in the majority of synovial tissue samples from patients with JIA, particularly in those with systemic-onset JIA. [18] If TNFβ plays a major role in the joint inflammation of systemic-onset JIA, then etanercept, neutralising both TNFα and TNFβ, may show efficacy against the arthritis.
As mentioned above, a vast body of evidence points to prominent IL-6 production as playing a major role in systemic-onset JIA, therefore suggesting that anti-IL-6 therapies may be effective in this disease. The available experimental approaches to the specific neutralisation of IL-6, including a humanised anti-IL-6 receptor antibody and IL-6 receptor antagonists, [33, 34] are under evaluation in preclinical and clinical settings.
Although preliminary studies have shown that etanercept is well tolerated in children with JIA, further data are needed to better define the toxicity profile of this drug and determine whether it can be safely administered for long periods of time in children. A more ready availability of etanercept will help to clarify these important issues.
Last but not least, because etanercept is significantly more expensive than previous drugs, the issue of its cost effectiveness compared with the traditional disease-modifying medications should be properly addressed, and its indications in the management of children with JIA must be precisely defined.
Conclusion
Etanercept is an important addition to the treatment of JIA. At present methotrexate remains, because of its effectiveness, tolerability and low cost, the drug of first choice for the treatment of children with JIA who fail to respond adequately to NSAIDs. However, the use of etanercept offers a promising alternative for patients who have persistently active arthritis despite treatment with methotrexate.
